尹强, 张振, 刘刘群, 李鹏, 马莉, 王鹏, 孙增峰, 李文良, 王晓光. 阿来替尼治疗ALK基因融合重排NSCLC脑转移瘤的临床疗效分析[J]. 中国肿瘤临床, 2020, 47(13): 661-665. DOI: 10.3969/j.issn.1000-8179.2020.13.344
引用本文: 尹强, 张振, 刘刘群, 李鹏, 马莉, 王鹏, 孙增峰, 李文良, 王晓光. 阿来替尼治疗ALK基因融合重排NSCLC脑转移瘤的临床疗效分析[J]. 中国肿瘤临床, 2020, 47(13): 661-665. DOI: 10.3969/j.issn.1000-8179.2020.13.344
shu
Yin Qiang, Zhen Zhang, Liu Qun, Li Peng, Ma Li, Wang Peng, Sun Zengfen, Li Wenliang, Wang Xiaoguang. Efficacy of alectinib for ALK-positive NSCLC brain metastases[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(13): 661-665. DOI: 10.3969/j.issn.1000-8179.2020.13.344
Citation: Yin Qiang, Zhen Zhang, Liu Qun, Li Peng, Ma Li, Wang Peng, Sun Zengfen, Li Wenliang, Wang Xiaoguang. Efficacy of alectinib for ALK-positive NSCLC brain metastases[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(13): 661-665. DOI: 10.3969/j.issn.1000-8179.2020.13.344
shu

阿来替尼治疗ALK基因融合重排NSCLC脑转移瘤的临床疗效分析

Efficacy of alectinib for ALK-positive NSCLC brain metastases

    摘要
  • 摘要:
      目的  探讨阿来替尼治疗ALK融合重排非小细胞肺癌（non-small cell lung cance，NSCLC）脑转移患者的疗效及不良反应。
      方法  回顾性分析2016年8月至2019年10月天津医科大学肿瘤医院34例以脑转移为首发的ALK基因融合重排NSCLC患者的临床资料，其中13例（38.2%）患者接受阿来替尼单药一线治疗。男性7例（53.8%），女性6例（46.2%），中位年龄51（35~72）岁。应用Kaplan-Meier分析其生存情况。
      结果  阿来替尼治疗ALK基因融合重排肺癌脑转移瘤，颅内中位无进展生存期（median progression-free survival，mPFS）为24.5个月。药物不良反应较轻。
      结论  在颅内可测量病灶得到局部治疗的基础上，阿来替尼作为ALK基因融合重排NSCLC脑转移患者的一线治疗方案，显著延长患者无进展生存期（progression-free survival，PFS）。

     

    Abstract:
      Objective   To investigate the effect of alectinib in the treatment of brain metastases from anaplastic lymphoma kinase(ALK)- positive non-small cell lung cancer (NSCLC).
      Methods   Thirty-four cases of ALK-positive NSCLC in Tianjin Medical University Cancer Institute and Hospital, between August 2016 to October 2019, were retrospectively analyzed. Thirteen cases received first-line single drug therapy (600 mg PO bid) of Alectinib. 7 cases (53.8%) were male, 6 cases were female (46.2%), the median age was 51 (35-72). The Kaplan-Meier method was used to examine progression-free survival (PFS).
      Results   The median progression-free survival (mPFS) of the alectinib group was 24.5 months, and the adverse drug reactions were mild.
      Conclusions   The use of alectinibas first-line treatment after the local treatment of measurable intracranial lesions significantly increased the PFS of patients with brain metastases from ALK-positive NSCLC.

     

    • HTML全文
    • 参考文献(18)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回